We are live on ! Find out more

HTFL

Heartflow Inc

HTFL

Market cap $4.25B

48.91 USD

-0.80

1.61%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

49.01

+0.10

0.2%

1 day

-1.61%

5 days

2.58%

1 month

79.29%

3 months

69.77%

6 months

104.39%

Year to date

68.83%

1 year

43.47%

5 years

70.12%

10 years

70.12%

About: HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Employees: 843

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.5%

Neutral 45.5%

Negative 9.1%

The Motley Fool

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

Baron SMID Cap ETF Q2 2026 Portfolio Activity

During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.

Baron SMID Cap ETF Q2 2026 Portfolio Activity

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

The Motley Fool

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

The executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100. The transaction reduced the insider's direct equity position by 10%, while total beneficial ownership decreased by 4%.

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

HeartFlow: An Impressive MedTech Growth Play

HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.

HeartFlow: An Impressive MedTech Growth Play

The Motley Fool

Why Heartflow Stock Soared Today

Heartflow's AI-powered platform could save countless lives. The company is growing at an impressive clip.

Why Heartflow Stock Soared Today

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

HeartFlow Inc. (NASDAQ:HTFL) shares are trading sharply higher Friday afternoon after the company reported better-than-expected second-quarter adjusted EPS results and raised its full-year financial outlook.

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

Investors Business Daily

This AI-Tied IPO Stock Just Broke Out On Its 'Outsized' Guidance Boost

Heartflow stock broke out Friday, helped by an "outsized" guidance raise and second-quarter beat.

This AI-Tied IPO Stock Just Broke Out On Its 'Outsized' Guidance Boost

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™